News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Wall Street analysts are showing bullish sentiment towards two healthcare stocks: Orchestra BioMed Holdings (OBIO) and Adagene (ADAG). H.C. Wainwright reiterated a Buy rating for Orchestra BioMed with a $10.00 price target, while LifeSci Capital maintained a Buy rating for Adagene with an $8.00 …
An investor group led by Invus Public Equities, L.P. has reported a 9.4% beneficial ownership stake in Nanobiotix S.A. (NBTX), comprising 4,483,275 ordinary shares and 345,099 pre-funded warrants. The warrants are exercisable at Euro 0.03 per share and expire in May 2036. This filing, …
Orchestra BioMed Holdings, Inc. (OBIO) recently reported Q2 results showing revenues significantly below expectations, though statutory losses were in line with forecasts. Analysts have since updated their models, projecting a substantial 99% reduction in 2026 revenues and an increase in per-share losses, indicating a …
Orchestra BioMed (NASDAQ:OBIO) reported a quarterly loss of $0.38 per share, missing analyst estimates by $0.03. Despite the earnings miss and negative financial metrics, the company's shares increased by 5.2% and insiders purchased a significant amount of stock. Analyst sentiment is mixed but generally …
Orchestra Biomed Holdings (NASDAQ: OBIO) reported second-quarter EPS of $-0.380
The average 12-month price target for Orchestra BioMed Holdings, Inc. (OBIO) stock has increased to $12.33, up from $12.17, according to estimates from six analysts. This new target suggests a potential upside of approximately 177% from its closing price on August 10. The consensus …
Orchestra BioMed announced its second-quarter 2026 financial results, highlighting progress in its two cardiovascular programs: AVIM Therapy and Virtue SAB. The company reported that its BACKBEAT trial for AVIM Therapy is on track to meet its target enrollment by Q3 2026, with primary data …
Orchestra BioMed Holdings reported a net loss of $24.1 million in Q2 2026, widening from the previous year, despite an 89% drop in revenue to $88,000. The loss was primarily due to increased research and development expenses for pivotal clinical trials. However, the company …
Orchestra BioMed reported its Q2 2026 financial results, including a net loss of $24.1 million, and provided updates on its pivotal clinical trials. The BACKBEAT Trial for uncontrolled hypertension is on track to enroll 284 patients by Q3 2026, with primary results expected in …
Orchestra BioMed Holdings, Inc. (OBIO) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.35 loss, though it was an improvement from a $0.5 loss a year ago. The company also missed revenue estimates, posting $0.09 million against …
Orchestra Biomed Holdings Inc (OBIO) has an earnings forecast score of 8.00, placing it 65th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $12.00, with a range from $10.00 to $20.00, indicating a "Buy" trend based on …
Qube Research & Technologies has revealed a 0.7% net short position in Nanobiotix, with the disclosure dated August 6, 2026. This news brief was generated by Public Technologies (PUBT) using AI and is based on original content published by Nanobiotix SA on August 7, …
Laurent Levy, CEO of Nanobiotix, discussed how a physics-based approach to drug delivery, exemplified by their NanoPrimer platform, could enhance therapeutic performance by optimizing particle behavior within the body. This method aims to complement existing biological therapies without adding undue complexity, offering a new …
Orchestra BioMed Holdings, Inc. executive Darren Sherman sold 15,000 shares of common stock on August 3, 2026, at a weighted average price of $4.09 per share under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Sherman directly holds 1,154,327 shares. The sale ranged …
Orchestra BioMed (OBIO) is projected to announce its Q2 2026 earnings before market open on Tuesday, August 11th, with analysts forecasting a loss of $0.35 per share and revenue of $138,000. The company previously beat EPS expectations but missed revenue targets in Q1. The …
An insider at Orchestra BioMed Holdings Inc. (OBIO) has filed to sell 15,000 shares of common stock under Rule 144, valued at $61,291.68, scheduled for August 3, 2026. The shareholder, Darren Sherman, also reported previous sales of 15,000 shares each on June 1, 2026, …
Orchestra Biomed Holdings Inc (OBIO) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 7.86% quarter-over-quarter to 42.19%, with Steven Cohen being the largest institutional shareholder.
This article provides a technical analysis of Orchestra Biomed Holdings Inc (OBIO), detailing its current price momentum score, support and resistance levels, and the status of various technical indicators and moving averages. The analysis suggests the stock is currently trading between identified support and …
Nanobiotix S.A., a clinical biotechnology company, announced its share capital and voting rights as of June 30, 2026. The company reported 50,825,682 shares outstanding and 54,486,890 theoretical voting rights, with 54,464,772 exercisable voting rights. This disclosure aligns with French financial regulations and provides transparency …
This page provides financial data for Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), specifically focusing on its price-to-book forward ratio. The content is primarily a data display with minimal narrative, indicating the company's financial overview on the TradingView platform.
Nanobiotix S.A. has published its voting rights and shares capital as of June 30, 2026, in accordance with French financial regulations. The company reported 50,825,682 shares outstanding, with 54,486,890 theoretical voting rights and 54,464,772 exercisable voting rights. Nanobiotix is a late-stage clinical biotechnology company …
Nanobiotix reported its share capital and voting rights as of June 30, 2026, in compliance with French regulations. The company had 50,825,682 shares outstanding, corresponding to 54,486,890 theoretical voting rights and 54,464,772 exercisable voting rights. This disclosure is made for transparency and threshold crossing …
The Qatar Investment Authority has reported beneficial ownership of 3,532,517 Nanobiotix SA Depositary Receipt S ADRs, representing 7.0% of the class. These ADRs are held with sole voting and dispositive power through its wholly-owned subsidiaries, QH Oil Investment LLC and Q Dutis Holding LLC. …
Search by ticker symbol or company name and select a result to open its chart.